CN1041276C - Drug for preventing common cold - Google Patents
Drug for preventing common cold Download PDFInfo
- Publication number
- CN1041276C CN1041276C CN93101972A CN93101972A CN1041276C CN 1041276 C CN1041276 C CN 1041276C CN 93101972 A CN93101972 A CN 93101972A CN 93101972 A CN93101972 A CN 93101972A CN 1041276 C CN1041276 C CN 1041276C
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- preparation
- granules
- zinc gluconate
- flu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Electrochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a new anti-cold medicine which is called xinkekang or xinbu keli. The present invention is a compound preparation, the drug ingredients (wt%) comprises 36 to 43 wt% of zinc gluconate, 54 to 65 wt% of ibuprofen and 0.5 to 1 wt% of chlorphenamine, the medicines and proper quantities of pharmaceutic adjuvants, such as starch, magnesium stearate or sugar are sieved and mixed, starch slurry or distilled water is added to the mixture and manufactured into mushes, the mushes are manufactured into granules by a nylon sieve, and the granules are processed into tablets, capsules or granules through ventilation and drying. The present invention is suitable for colds not caused by bacteria and influenza caused by influenza viruses, and has the functions of antivirus, refrigeration and analgesia; the total effective rate reaches more than 93.8% through the clinical verification, and the body temperature can return to normal within 13.7 hours in average after administration.
Description
The present invention relates to a kind of compound preparation of anti-flu.
Flu is a kind of commonly encountered diseases, frequently-occurring disease, generally is divided into two big classes, and a class is the common cold that non-bacterial infection causes; One class is the flu that influenza virus causes.Symptom is generally heating, headache, pantalgia, weak, nasal obstruction, watery nasal discharge, it is painful to shed tears, cough, swallow, sneeze etc.Though the medicine of treatment flu at present is various in style, actual is based on antiviral agents and antipyretic analgesic.Aspect resisiting influenza virus, use maximum persons for Moroxydine, but its evaluation of clinical curative effect differs, in some countries, do not use, China also seldom uses.Antipyretic analgesic commonly used is used maximum have APC, somedon, SUXIAO GANMAO JIAONANG, GANMAOTONG sheets etc., but its pair problems in role is more and more paid close attention to by common people.Other medicine for the treatment of flu clinically also nothing more than be play the same tune on different musical instruments or curative effect significantly poison to pay effect not bigger, harmful.The inventor has consulted amount of literature data for this reason, finds that zinc gluconate can suppress duplicating of rhinovirus, herpes simplex virus effectively, induces endogenous interferon, improves the human body immune function, and weak frequent flu, influenza are had certain curative effect.But also affirm and use as Coritab at home.Ibuprofen be a kind of clinical use for many years, determined curative effect, the antipyretic analgesic that the effect of paying is very little is used for the treatment of flu through international online retrieval and there is no bibliographical information at home and abroad.
The objective of the invention is to overcome the deficiency that there is single drug effect in existing cold medicine provides a kind of novel anti coldrex of safe and effective, treating both the principal and secondary aspects of a disease for the influenza patient.Another purpose of the present invention is to collect the zinc gluconate antiviral and the ibuprofen antipyretic-antalgic is an one, and a kind of compound preparation of anti-flu is provided.
Implementing technical scheme of the present invention is:
A kind of compound preparation of anti-flu is characterized in that it comprises that the medicament with following percentage by weight forms through composite, zinc gluconate 36～43%, ibuprofen 54～65%, chlorphenamine 0.5～1, more than each components contents sum be 100%.This compound preparation also can allocate starch into and an amount of magnesium stearate is made oral tablet, also can allocate Icing Sugar into and make oral granule with an amount of distilled water.
Can be processed into following dosage form by above-mentioned prescription:
(1) tablet
Prescription: (every consumption, the mg of unit)
Zinc gluconate 100 ibuprofen 150 chlorphenamine 2 starch, 45 starch slurries (8%) are an amount of
Magnesium stearate is an amount of
Preparation technology: above-mentioned supplementary material is crossed 80 mesh sieves, dilute chlorphenamine gradually also by behind 80 mesh sieves with starch by the equivalent method of progressively increasing, place the mixer mixing altogether with zinc gluconate, ibuprofen, add 8% starch slurry, stir and make soft material, reuse 14 order nylon mesh are made granule, in 50～60 ℃ of left and right sides aeration-dryings, add the magnesium stearate mixing with 14 mesh sieve granulate, content is measured in sampling, it is heavy that grain is calculated in qualified back, selects 9mm plane punch die tabletting for use.
(2) electuary (granule)
Prescription: (every bag of consumption, the mg of unit)
Zinc gluconate 100 ibuprofen 150 chlorphenamines 2 Icing Sugar 4748 distilled water are an amount of
Preparation technology: Icing Sugar is crossed 100 mesh sieves, dilute chlorphenamine gradually by the equivalent method of progressively increasing, behind 80 mesh sieves, place the mixer mixing altogether excessively with zinc gluconate, ibuprofen, add distilled water, stir and make soft material, reuse 14 mesh sieves are made granule, in 40 ℃ of left and right sides aeration-dryings, dry granular is crossed 14 mesh sieve granulate, mixing, content is measured in sampling, the encapsulation of qualified back.
The present invention compares with existing cold medicine has following advantage:
1, the present invention has good analgesic, analgesia, antiinflammatory, the antiallergic antivirus action, can suppress rhinovirus, virus replications such as herpes simplex virus, suppress basophilic leukocyte and discharge histamine, common cold and influenza that non-bacterial infection is caused all have significant curative effect, through pharmacodynamics test, show 305 routine clinical verifications, this preparation both can suppress viral breeding from the cause of disease, infect, play antipyretic effect from symptom again, total effective rate reaches more than 93.8%, reduced to normal in average 13.7 hours after taking medicine, and no longer multiple the liter do not found obvious adverse reaction yet in therapeutic process.A kind of ideal medicament of the various flu of treatment of not only having taken stopgap measures but also effected a permanent cure so this preparation be can yet be regarded as.
2, after each composition of this medicine cooperates, not only do not have antagonism, and produce synergism between each component, curative effect is further strengthened.Or use effective time to prolong.Prove that according to clinical effectiveness this prescription has the reasonability of height, is better than general drug combination.
In order whether to verify this preparation to catching a cold effectively, the inventor has carried out animal experiment to multiple component in the compound preparation to drug effect or toxicity, now enumerates three examples and is summarized as follows:
One, this preparation is to the influence of fever in rabbits due to the typhoid fever triple vaccine
The result shows, after family's rabbit ear vein injection typhoid fever is paid the typhoid fever first and second triple vaccine 0.5ml/kg, body temperature continues to raise in the matched group 6 hours, and this preparation group body temperature in 6 hours all is starkly lower than matched group (P＜0.01) and illustrates that this preparation has significant refrigeration function.
Two, this preparation is to the influence of lumbar injection acetic acid induced mice hot body reaction
Use 0.1% acetum, press 0.15ML/ lumbar injection, write down the number of times of hot body in incubation period of every mice hot body reaction and every the mice 5 minutes, and respectively organize the quantity of mice hot body.
The result shows: this preparation has good analgesic activity.
Three, this preparation is to the influence of influenza virus Lung Index of mice infected by Influenza virus
Divide four groups at random promptly with Kunming mouse: matched group, zinc gluconate group, this preparation group (zinc gluconate 0.3mg/10g+ ibuprofen 1.2mg/10g+ chlorphenamine 16 μ g/10g) and double this preparation of amount group.Every day gastric infusion once, continuous five days.In experiment second day, under etherization, the equal collunarium viral infection of various animals animal.Viral species is that influenza A virus Mus lung adapted strain FM1 dosage is 10LD300.After infection was weighed in back the 4th day, open breast and get lung, claim breast re-computation lung index (mouse lung weight/mice body * 100%).The big expression virus of index causes that the pneumonopathy degree is serious.The result shows that this preparation group lung index is lower than matched group, illustrates that this preparation has obvious inhibitory action to influenza infection induced mice pneumonia.
Clinical observation on the therapeutic effect
One, clinical trial unit: People's Hospital of Shanxi Prov.'s Respiratory Medicine.Clinical therapeutic efficacy for this preparation granules of treatment flu new drug of observing the development of Datong City, Shanxi Province spark pharmaceutical factory, my institute holds Department of Public Health of Shanxi Province and entrusts, take the lead by BJ Union Hospital and to form cooperation unit, urge my institute's Respiratory Medicine to share 100 routine satisfactory common cold patients, now finished the every index of agreement regulation clinical observation, the result is as follows:
1, medicament sources: provide each two bags of this preparation (zinc gluconate 100mg, chlorphenamine 2mg, ibuprofen 150mg are a bag) to take after mixing it with water by spark pharmaceutical factory, every day three times, logotype two days was a course of treatment.
2, the object of observation: all have flu or symptom such as similar heavy cold such as fever, watery nasal discharge, nasal obstruction, sneeze, itching throat, cough, pantalgia, headache, disease patient such as weak, and body temperature in morbidity more than 37.5 ℃ within 24 hours, do not do therapist and all belonged to it.
3, criterion of therapeutical effect:
(1) recovery from illness: body temperature is reduced to normally and is no longer raise, and clinical symptoms disappears entirely.
(2) produce effects: body temperature is reduced to normally and is no longer raise, and faces shape symptom project and reduces by half at least.
(3) effective: the body temperature peak descends 1 ℃ at least, and clinical project reduces to some extent.
(4) invalid: body temperature does not fall, and clinical symptoms is not improved substantially.
4, observed result: my institute observes 100 examples (real the observe 105 examples) patient that meets the requirements altogether, wherein male 51 examples, women 54 examples, the age minimum be 16 years old, be 80 years old to the maximum, the mean age is 36 years old.The result is: this preparation granules orally taken for curing flu, satisfactory effect.Recovery from illness 40 examples account for 38.10% among the 105 routine patients; Produce effects 52 examples account for 49.52%; Effective 9 examples account for 8.57%; Invalid 4 examples account for 3.81%, and total effective rate 96.19%, its cooling-down effect occurred between 4～48 hours, and the cooling mean is 18.53 ± 9.26 hours.Other is as all there were significant differences (P＜0.01) before and after coryza symptom and General Symptoms (except that the symptom of the feeling sick) treatment.This medicine shows that in clinical use individual patient has slight nauseating and slight drowsy sense, but does not influence operate as normal and life.Still think this medicine can yet be regarded as one the treatment good remedy for a cold.
Two, BJ Union Hospital of clinical trial unit
The clinical observation on the therapeutic effect of this medicine is responsible for by BJ Union Hospital, and first Affiliated Hospital of Shanxi Medical College and People's Hospital of Shanxi Prov. finish jointly.Wherein BJ Union Hospital finishes treatment and organizes 100 routine matched group 104 examples, and Shanxi Province two hospitals finish treatment group 100 example and 105 examples respectively.
305 examples are organized in treatment, wherein male 169 examples, and women 136 examples are divided into two groups, and the child organized for 24 6.7 ± 3.4 years old mean age of example; 281 30.7 ± 13.2 years old mean age of example of adult group.
Matched group 104 examples, wherein male 65 examples, woman's 39 examples are divided two groups, and the child organized for 34 7.3 ± 3.2 years old mean age of example.
The object of observation: the same
Medicine: this preparation of adult's clothes electuary whenever comprises zinc gluconate 100mg, ibuprofen 150mg, chlorphenamine 2mg.The contrast electuary whenever comprises APC0.3g.Instructions of taking: every day 3 times, each 2 bags.This preparation of children's electuary whenever comprises zinc gluconate 50mg, ibuprofen 75mg, chlorphenamine 1mg.The matched group electuary whenever comprises APC0.1g, instructions of taking, every day 3 times, 1～3 years old each 1 bag; 4～6 years old each 1.5 bags, each 2 bags more than 7 years old.Time of Administration is two days (6 times).
Criterion of therapeutical effect: the same
The observation of curative effect result: data form slightly
Conclusion:
This group clinical observation material shows: this preparation electuary treatment acute upper respiratory tract infection total effective rate reaches 93.8%, the average 13.7 hours body temperature in back of taking medicine is reduced to normally, remove the common cold symptom and improve headache, pantalgia, General Symptoms effect such as weak is obvious, and matched group (aspirin) total effective rate is 69.2%, the average 16.2 hours body temperature in back of taking medicine is reduced to normally, only there are 2 doing well,improvings obvious after taking medicine, two groups of clinical observation on the therapeutic effect, the treatment group obviously is better than matched group, does not find obvious adverse reaction in this preparation electuary application process.
Claims (3)
1, a kind of compound preparation of anti-flu is characterized in that it comprises the zinc gluconate 36～43% with percentage by weight as described below, ibuprofen 54～65%, chlorphenamine 0.5～1%, more than each components contents sum be 100%.
2, a kind of oral tablet of anti-flu contains zinc gluconate 100, ibuprofen 150, chlorphenamine 2, starch 45, concentration in milligram in it is characterized in that every and is that 8% starch slurry is an amount of, magnesium stearate is an amount of.
3, a kind of oral granule electuary of anti-flu, the zinc gluconate 100, ibuprofen 150, chlorphenamine 2, Icing Sugar 4748, the distilled water that contain in milligram in it is characterized in that every bag are an amount of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93101972A CN1041276C (en) | 1993-02-27 | 1993-02-27 | Drug for preventing common cold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93101972A CN1041276C (en) | 1993-02-27 | 1993-02-27 | Drug for preventing common cold |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1091638A CN1091638A (en) | 1994-09-07 |
| CN1041276C true CN1041276C (en) | 1998-12-23 |
Family
ID=4983884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93101972A Expired - Fee Related CN1041276C (en) | 1993-02-27 | 1993-02-27 | Drug for preventing common cold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1041276C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099807A (en) * | 2011-11-15 | 2013-05-15 | 海南澳美华制药有限公司 | Compound zinc gluconate and ibuprofen oral-administration composition for covering bitter taste and improving ibuprofen dissolution |
| CN102488689B (en) * | 2011-12-12 | 2013-03-13 | 南京臣功制药股份有限公司 | Compound zinc gluconateand ibuprofen granule capable of curing cold and preparation method thereof |
| CN103239446B (en) * | 2013-05-13 | 2014-11-12 | 中国科学院武汉病毒研究所 | Application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503070A (en) * | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
-
1993
- 1993-02-27 CN CN93101972A patent/CN1041276C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503070A (en) * | 1981-07-31 | 1985-03-05 | Eby Iii George A | Method for reducing the duration of the common cold |
Non-Patent Citations (1)
| Title |
|---|
| 新编药物学 第十版 1979.9.1 陈新谦主编；人民卫生出版社出版 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1091638A (en) | 1994-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021155751A1 (en) | Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof | |
| KR101364803B1 (en) | Pharmaceutical composition containing EPHEDRAE HERBA for treating bronchitis and preparation method thereof | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| CN113546089B (en) | Application of 1-ethyl-3, 7-dimethyl xanthine in preparation of medicine for treating pneumonia | |
| Khakoo et al. | Effect of inosiplex (Isoprinosine®) on induced human influenza A infection | |
| CN1041276C (en) | Drug for preventing common cold | |
| JPH08512311A (en) | Arsenic medicine for treating chronic fatigue syndrome | |
| Tannock et al. | A study of intranasally administered interferon A*(rIFN-α2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers | |
| US6514960B1 (en) | Use of bismuth subgallate in inhibition of production of nitric oxide synthase | |
| JP4384435B2 (en) | Sneezing suppression composition | |
| CN1572298B (en) | Arbidol containing compound preparation | |
| AU749169B2 (en) | A method for preventing the onset of asthma | |
| CN1066064C (en) | Analgesic-antipyretic medicine and preparing method therefor | |
| CN1285346C (en) | Chinese medicine for treating AIDS | |
| CN108542904A (en) | A kind of combination medicine for treating ulcerative colitis | |
| CN1097139A (en) | The compounded solid oral medicine of treatment upper respiratory tract infection | |
| CN1040063C (en) | Zinc gluconate for calming sathma and cough | |
| JPH0967256A (en) | Drug for common cold | |
| CN1293881C (en) | Compound antitussive | |
| CN1255160C (en) | Health food for preventing and treating influenza | |
| KINSMAN et al. | Meningococcemia: a description of the clinical picture and a comparison of the efficacy of sulfadiazine and penicillin in the treatment of thirty cases | |
| CN112641918A (en) | Application of ginger powder in preparation of medicine for treating viral influenza | |
| CN115844911A (en) | Combined pharmaceutical composition for treating ulcerative colitis | |
| CN1267537A (en) | Medicinal composition for asthma and trachitis and its preparation | |
| CN115944621A (en) | Application of genistein in preparation of medicine for preventing or treating leukopenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: DATONG XINGHUO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: XINGHUO PARMACEUTICAL FACTORY, DATONG CITY |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Datong spark Pharmaceutical Co Ltd Patentee before: Xinghuo Parmaceutical Factory, Datong City |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CI01 | Correction of invention patent gazette |
Correction item: Termination of patent right Correct: Cancellation of patent right False: Termination of patent right Number: 18 Page: 478 Volume: 20 |
|
| ERR | Gazette correction |
Free format text: CORRECT: CESSATION OF PATENT RIGHT; FROM: CESSATION OF PATENT RIGHT TO: CANCEL CESSATION OF PATENT RIGHT |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 19981223 Termination date: 20110227 |